Cabaletta Bio announced multiple presentations at the ASGCT 2026 Annual Meeting in Boston, showcasing clinical and manufacturing data on rese-cel, their investigational CAR T cell therapy for autoimmune diseases. Key highlights include data on rese-cel without preconditioning in pemphigus vulgaris, automated manufacturing using the Cellares Cell Shuttle platform, and product quality comparisons between healthy donors and patients. These presentations underscore Cabaletta's progress in developing targeted cell therapies aimed at resetting the immune system to treat autoimmune conditions. The company continues advancing rese-cel through its RESET clinical program with upcoming data releases expected to support further development and potential regulatory submissions.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
Lockheed Martin Ventures, the $1 billion venture capital arm of Lockheed Martin, is expanding into the UK and Europe with a new London office. It plans to invest at least $100 million in defense technology startups to strengthen transatlantic defense...
